ceritinib

08/20/2020 - "[Safety and Preliminary Efficacy of Ceritinib 450 mg with Food in Chinese ALK-positive Non-small Cell Lung Cancer]."
10/01/2015 - "The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer."
01/01/2022 - "Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study."
02/01/2018 - "[Result of Clinical Trials of Ceritinib in Patients with ALK-Rearranged Non-Small-Cell Lung Cancer and Management of the Adverse Events]."
08/10/2017 - "Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement."

01/01/2021 - "Ceritinib was effective for the relapsed tumor and treatment continued well for 4 years. "
12/01/2021 - "Here, we report the safety, pharmacokinetics, and efficacy of ceritinib in paediatric patients with ALK-positive malignancies. "
02/15/2021 - "Meanwhile, B3 showed improved anticancer activity in vitro comparing with LDK378 and the antiproliferative activity to xenograft tumor model was acceptable. "
01/01/2021 - "Further, treatment with ceritinib in the NPM1-ALK+ ALCL xenograft model resulted in tumor regression and improved survival. "
06/01/2017 - "Long-term administration of ceritinib with PPIs does not adversely affect the PK and efficacy of ceritinib in ALK-positive cancer patients."

01/01/2021 - "Interestingly, the ALK inhibitor Ceritinib decreased mTOR activity and increased GFP-WIPI1 dot formation in H3122 and H2228 EML4-ALK+ lung cancer cells, suggesting autophagy activation. "
01/01/2017 - "Ceritinib is a highly selective ALK inhibitor and shows promising efficacy in non-small cell lung cancers (NSCLC) harboring the ALK gene rearrangement. "
12/01/2016 - "Molecular dynamics simulations reveal the allosteric effect of F1174C resistance mutation to ceritinib in ALK-associated lung cancer."
07/01/2015 - "Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer."
07/01/2014 - "Ceritinib gains FDA approval for lung cancer."

01/01/2016 - "A second-generation ALK inhibitor, such as ceritinib, is also effective in overcoming this resistance in treating those with ALK-positive uveal metastases."
04/01/2017 - "In clinical trials, ceritinib has demonstrated durable responses and progression-free survival in ALK-inhibitor-pre-treated and -naïve NSCLC patients, including high overall and intracranial response rates in those with central nervous system metastases. "
01/01/2017 - "At ceritinib initiation, 44 patients had multiple distant metastases, most commonly in the liver (60%), bone (53%), and brain (38%). "
04/01/2016 - "A confirmatory phase 2 clinical trial is ongoing to assess ceritinib activity in patients with ALK-rearranged NSCLC and brain or leptomeningeal metastases. "
01/01/2016 - "However, because the bone metastases started progressing again and he developed bilateral ocular metastases, he was switched to ceritinib. "

01/01/2022 - "Ceritinib showed antitumor activity in patients with ALK+ NSCLC with active brain metastases and/or leptomeningeal disease, and could be considered in the management of intracranial disease. "
01/01/2020 - "Eligible patients (including those with asymptomatic or neurologically stable brain metastases) received oral ceritinib (750 mg/day, fasted). "
08/30/2019 - "Our data suggest ceritinib as a promising drug for the treatment of IGF-driven brain tumors."
02/01/2018 - "The method was successfully applied to assess ceritinib brain tumor penetration, as assessed by the unbound drug brain concentration to unbound drug plasma concentration ratio, in patients with brain tumors."
02/01/2018 - "A rapid, sensitive, and robust reversed-phase liquid chromatography with tandem mass spectrometry method was developed and validated for the determination of total and unbound ceritinib, a second-generation ALK inhibitor, in patient plasma and brain tumor tissue samples. "